Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.50 |
| ▸ | SYK | P43405 | 17/20 | 0.45 |
| ▸ | PLK1 | P53350 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19575438 | 0.87 | TAS2R14 (0.51) | TAS2R14SYK | |
| SCHEMBL21004286 | 0.82 | TAS2R14 (0.47) | TAS2R14SYK | |
| SCHEMBL21004276 | 0.81 | SYK (0.50) | TAS2R14SYKPLK1 | |
| SCHEMBL19575435 | 0.80 | PLK1 (0.60) | TAS2R14SYKPLK1 | |
| SCHEMBL21004550 | 0.77 | SYK (0.49) | TAS2R14SYK | |
| SCHEMBL19554381 | 0.75 | SYK (0.55) | TAS2R14SYKPLK1 | |
| SCHEMBL21004275 | 0.73 | TAS2R14 (0.46) | TAS2R14SYKPLK1 | |
| SCHEMBL19575360 | 0.73 | TAS2R14 (0.46) | TAS2R14SYKPLK1 | |
| SCHEMBL19553899 | 0.72 | SYK (0.55) | TAS2R14SYK | |
| SCHEMBL16750016 | 0.72 | SYK (0.71) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577362-B2 | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases | GENOSCIENCE PHARMA (FR) | 2020-03-03 | — | — | US | disclosed |
| US-20190144437-A1 | SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | GENOSCIENCE PHARMA (FR) | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144437-A1 | SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | NQO2, RECQL, CCNO | TAS2R14 3545/4885SYK 2562/4885PLK1 319/4885 |
| US-10577362-B2 | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases | NQO2, RECQL, CCNO | TAS2R14 3545/4885SYK 2562/4885PLK1 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.